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Prenatal diagnosis (PND) may be complicated with sample mix-up; maternal cell contamination, non-
paternity and allele drop out at different stages of diagnosis. Aneuploidy screening if combined with 
PND for a given single gene disorder, can help to detect any common aneuploidy as well as aiding 
sample authenticity and other probable complications which may arise during such procedures. This 
study was carried out to evaluate the effectiveness of a novel panel of STR markers combined as a 
multiplex PCR kit (HapScreen™ kit) for the detection of β-thalassemia, aneuploidy screening, ruling 
in/out maternal cell contamination (MCC), and sample authenticity. The kit uses 7 STR markers linked 
to β-globin gene (HBB) as well as using 9 markers for quantitative analysis of chromosomes 21, 18, 13, 
X and Y. Selection of the markers was to do linkage analysis with β-globin gene, segregation analysis 
and to perform a preliminary aneuploidy screening of fetal samples respectively. These markers (linked 
to the β-globin gene) were tested on more than 2185 samples and showed high heterozygosity values 
(68.4–91.4%). From 2185 fetal cases we found 3 cases of non-paternity, 5 cases of MCC, one case of 
sample mix-up and one case of trisomy 21 which otherwise may have end up to misdiagnosis. This 
kit was also successfully used on 231 blastomeres for 29 cases of pre-implantation genetic diagnosis 
(PGD) and screening (PGS). The markers used for simultaneous analysis of haplotype segregation and 
aneuploidy screening proved to be very valuable to confirm results obtained from direct mutation 
detection methods (i.e. ARMS, MLPA and sequencing) and aneuploidy screening.
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β-thalassemia (β-thal) is the most common autosomal recessive disease in the world, particularly in the Middle 
East1. It is estimated that there are nearly 80 million carriers of β-thal worldwide. There would be approximately 
60,000 affected babies born annually worldwide if no prevention program was implemented2,3. Carrier prevalence 
in Iran, with a population of about 80 million, is estimated to be 3–4 million (4–5%), with a broad spectrum of 
mutations4. Considering 1.5 million births per a year, one would expect to see birth of about 700–800 affected 
children, however, this number has been reduced to less than 150 since a nationwide prevention program was 
implemented5.
PND (prenatal diagnosis) is the method of choice for the prevention of new cases in carrier couples. PND has 
been in practice for the past several decades4,6 and as early as 1993 in Iran7. PND is a complicated process which 
poses misdiagnosis for various reasons including sample mix-up, non-paternity, maternal cell contamination, 
etc. Evaluation of the mentioned issues is essential in most PND cases and requires time and money otherwise 
misdiagnosis may occur.
PND usually requires invasive fetal sampling; therefore, to prevent invasive fetal sampling, preimplantation 
genetic diagnosis (PGD) is used as an established procedure to detect genetic disorders at the embryonic stage. 
PGD enables us to simultaneously check blastomeres for the disease gene alone or combined with HLA typing 
(using linked STR markers for haplotyping), aneuploidy detection and gender selection8,9.
In more than a decade, clinical validity of QF-PCR has been established as a rapid technique for aneuploidy 
diagnosis or exclusion of aneuploidy of chromosomes 13, 18, 21, X or Y10 for at-risk pregnancies as well as in PGS 
(preimplantation genetic screening). In most western and many other countries including Iran, every pregnant 
woman has to be screened for chromosomal aneuploidy11.
In this research, we validated a panel of multiplex-PCR based STR genotyping kit (i.e. Hapscreen kit from 
Genetek Biopharma, Berlin, Germany, GT) which uses STR markers closely linked to the β-globin gene to aid 
the diagnose of β-thal as a linkage approach for increasing the accuracy of results obtained by direct method (e.g. 
Sanger sequencing, MLPA or ARMS methods). According to the manufacturer’s claim, to enhance the function-
ality of this panel, different markers from chromosomes of 13, 18, 21, X, and Y have been added to the above 
panel. Addition of the mentioned markers facilitate aneuploidy screening, detecting maternal cell contamination, 
confirming fetal sample authenticity in addition to the diagnosis of β-thal simultaneously.
Materials and Methods
Samples preparation. The study was approved by the ethics committee of Kawsar Human Genetic Research 
Center. We confirm that all methods were performed in accordance with the relevant guidelines, regulations or 
protocols. All couples who had applied for PND or PGD were initially visited by a clinical geneticist and their 
genetic and reproductive history was determined and probable diagnostic choices were discussed.
After obtaining informed consent, different samples from chorionic villus (CV) or blastomeres were obtained 
by the specialists. DNA was extracted from CV samples using DNA Isolation kit (Kawsar Biotech Co., Tehran, 
Iran, KBC) following manufacturer’s protocol. Genomic DNA was extracted from blood samples by standard 
salting out method12.
STR identification and selection. At initial phase, 15 STR markers linked to the β-globin gene were 
selected using UniSTS database and UCSC genome browser. Six of the selected STRs markers were novel using 
TRF(Tandem Repeats Finder)13. All selected STRs were tri or tetra nucleotide repeats to increase the accuracy 
of diagnosis and reduce the stutter artifacts. All primers were designed using Gene Runner software v3.0514 and 
synthesized and labeled commercially. The sequences of these primers are in the province of Genetek Biopharma 
company. Afterward, 100 unrelated healthy individuals were genotyped to assess genotype frequency for each 
STR marker. Finally, seven markers were chosen to use in kit manufacturing.
Multiplex-PCR. We obtained GT-HapSceen, Aneusure (a QF PCR kit) and GT-Detector (a human DNA 
profiling kit) Kits form GeneTek (GeneTek Biopharma, Berlin, Germany, GT). Multiplex-PCR optimization was 
performed for blood samples and single cell blastomeres separately according to manufacturer’s recommendation 
and protocols (though the manufacturer had not suggested its use in PGD/PGS). PCR products were analyzed on 
2% (w/v) agarose gel (KBC) prior to running on Genetic Analyzer 3130 XL (Thermo Fisher Scientific, US, TF) to 
check the quality of PCR products.
Haplotype phasing. In order to phase haplotypes, we either used information for each marker from cou-
ples’ affected child and if there was no child then a carrier (based on CBC and A2 blood test results or confirmed 
mutation testing) parent of each partner was used. We have the habit in putting the mutated alleles and therefore 
haplotype on the left side of the bar (based on the affected child’s haplotype and pattern of inheritance, from the 
father or mother) and draw each allele for each individual and writing the mutation carrying allele on the left side 
of the bar. This will be carried out until all alleles are place in either side of the bars. However, for chromosome 
13, 18, 21, X and Y we only draw alleles based on haplotypes but try to put paternal ones on the left side of the bar.
Fragment analysis. 1 µ of each PCR product was mixed with HiDi Formamide and GT-500 size standard 
(GT) denatured at 95 °C for 3 min and snap cooled on ice for 5 min. The denatured PCR products were then 
separated and detected using an ABI 3130 XL or 3500 XL Genetic Analyzer (TF). Data were analyzed using 
Genemapper software (TF).
Statistical analysis. Allele frequencies for each STR loci, the power of discrimination (PD)15 and the power 
of exclusion (PE)16, were computed using the PowerStatsV12 Software17 and Gene Alex18. The polymorphic infor-
mation content, the expected and observed heterozygosity, and the deviation from the Hardy–Weinberg equilib-
rium (HWE) were calculated based on the Fisher’s exact test method15.
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Results
Prenatal diagnosis and PGD outcomes. Couples who are either confirmed carriers of β-thal or are sus-
pected of being carrier of β-thal are counseled and are referred for PND. Mutation detection is usually carried out 
by testing both couple or their affected child by either ARMS method19,20, Sanger sequencing or MLPA. We also 
would haplotype all cases of confirmed β-thal using RFLP or SNP markers linked to β-globin gene21–23.
For haplotyping, we would use phasing information from the couple, their affected child (if present or avail-
able) and/or their parents. Haplotyping have been an essential part of our PND for thalassemia and most other 
diseases. When the Hapscreen kit became available, we switched to Hapscreen for almost every cases of PND. 
Therefore, every PND is performed using both direct mutation detection and haplotyping.
More than 2185 fetal cases of β-thal have been diagnosed using the above procedures. From these, 528 fetal 
samples were homozygous normal, 1105 heterozygous carriers and 552 were affected and all of them were 
referred for therapeutic abortions. On the other hand, 949 out of 2185 cases were screened for aneuploidies using 
Hapscreen kit. The PND outcomes were 227 homozygous normal, 494 heterozygote and 228 affected fetuses. 
From 949 fetal cases, 917 were singleton, 31 were twin and one case was triplet. Among 2185 fetal cases we identi-
fied 5 cases of non-paternity, 3 cases of sample mix-up (misdiagnosis was prevented based on Hapscreen results), 
3 cases of maternal cell contamination (MCC) and one case of trisomy 21 (suggested by Hapscreen result and 
confirmed by QFPCR). Some of these cases are shown in Figs 1–3 and elaborated below when figures are being 
explained.
In total, we analyzed more than 238 blastomeres from 29 PGD cases. Our analysis showed that 51 blastomeres 
were homozygous normal, 82 were carriers, 55 were affected (not transferable) and the rest (50 blastomeres) did 
not produce any result. This may have been either the sample had been deliberately blanked by the IVF center, or 
no cells had been transferred into the tubes (either the cell had been lysed before transferring or had been released 
onto the tubes wall).
In total 124 embryos were transferable, though in few cases the parents had decided only to transfer homozy-
gous normal cells. To date 11 pregnancies had occurred, two was miscarried, 3 are ongoing and 5 healthy babies 
have been born.
Heterozygosity assessment of the markers. Allele frequencies and heterozygosity of 15 β-globin STR 
markers were obtained by genotyping 100 unrelated healthy individuals prior to use them in haplotyping fetal 
samples. In total, 133 different alleles were detected (data is shown in Table 1).
The observed range of allele frequencies varied. According to our study, D11HBBSU3.2 marker had the 
highest heterozygosity (96.4%) among the 15 studied STR markers. D11HBBSD1.06 marker with 90.9% fre-
quency rate was the second most heterozygous marker. The allele size ranges and heterozygosity of STR loci 
are listed in Table 1. The PD ranges were from 0.76 to 0.93 for D11HBBSD11.2 and D11HBBSU3.2 loci respec-
tively. Estimating allele and genotype frequencies showed no deviation from the Hardy–Weinberg equilibrium 
Figure 1. Capillary electrophoresis result of a multiplex PCR for 16 selected STR markers. The name of each 
marker is written above the peaks. The data is generated using HapScreen HBB. These types of data have been 
used to draw pedigree with haplotypes (e.g. Figs 2, 3 and 5).
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(P < 0.001). Other statistical findings are shown in Table 1. Allele frequencies for QF-PCR part of the kit were 
not calculated, though are available since they are generated simultaneously in every test (Fig. 1) and are avail-
able elsewhere since they are commonly used in most commercially available QFPCR kits including AneuSure 
(GT)24–28.
Markers used in PND and PGD. Since the initial use of the β-globin HapScreen kit, we have been using it 
routinely in almost all cases of PNDs for β-thal. It has been extremely valuable to track the disease gene segrega-
tion and also confirm results obtained by other methods (e.g., ARMS or Sanger sequencing), paternity, sample 
authenticity, or even uniparental disomy29.
Also it has been shown to be extremely valuable when the disease is confirmed by other methods (e.g. CBC, 
HBA2 level and clinical presentation). Indeed in several cases the initial investigation of the β-globin gene by 
sequencing or MLPA had not resulted in identifying a definite causal mutation in several families with CBC and 
HbA2 levels similar to those of β-thal carriers, who had been referred to our lab for either PND or PGD, despite of 
our center being the most experienced lab in the country5. Therefore, for the purpose of PND, indirect approaches 
such as using RFLP, SNP or STR markers can be used21,30. In addition, 29 other families were considered as a 
candidate for PGD, with a medical history of at least two abortions due to fetuses being diagnoses as affected with 
β-thal and parents’ desire was not to go through natural pregnancy which necessitates PND.
Our policy for carrying our PND or PGD is that the haplotypes from family members should be determined 
to track the mutant allele even before fetal sampling and in every case of PGD before starting IVF procedure.
Below several cases have been given to clearly demonstrate our approaches. For example, Fig. 2 shows results 
of haplotyping for a β–thal family with a triplet pregnancy. We knew that the personI-1 (the father) carries 
Figure 2. A β–thalassemia case with triplet pregnancy. I-1 (the father) carries IV S-I-5 and I-2 (the mother) 
carries Fr8–9 mutations. II-1 is a female carrier fetus affected with trisomy 21. II-2 and II-3 are carrier female 
and male fetuses respectively. The last two fetuses are very similar in their haplotypes. The only difference is in 
Amelogenin (AmXY) marker which helped us in differentiating these two fetuses from each other. Therefore, 
confirming sample authenticity and MCC is ruled out for all three fetuses. “NL” means normal or wild type 
allele.
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IVS-1-5 mutation and I-2 (the mother) carries a frameshift 8–9 (Fr8–9) mutation. Haplotyping in the pedigree 
shows that II-1 is a female carrier fetus affected with trisomy 21. II-2 and II-3 are female and male carrier fetuses 
respectively. The last two fetuses are very similar in their haplotypes. The only difference is in their Amelogenin 
(AmXY) region which helped us to differentiate these two fetuses from each other (confirming sample not being 
mixed-up). Other confirmatory test also confirmed sex typing results. Sample authenticity is confirmed by shared 
alleles between the parents and fetuses and also MCC is ruled out for all three fetuses.
In Fig. 3 we have another case of β-thal. In this case, haplotyping confirmed non-paternity. Since the carrier 
couple shares the same mutation and haplotype, the fetus shares one of the haplotypes but the other one is not 
present in either the mother or the father, confirming non-paternity but sample authenticity since it had mater-
nal haplotype. No chromosomal aneuploidy was observed. We do not have the habit in informing the parents 
in non-paternity cases, though no official rule is in place to follow. Having extra markers from the Aneusure 
QF-PCR kit (GT) included in this panel provided us the opportunity to rule out or confirm sample authenticity 
and non-paternity. For further confirmation, paternity testing was performed using GT-Detector kit (GT). As 
presented in Fig. 4, the paternity was rejected by this approach as well.
The final example is a case of PGD for β-thal which is shown in Fig. 5. II-7 and II-9 blastomeres are not 
affected with thalassemia but they suffer from monosomy of 21 and trisomy of 21 respectively. Therefore, the only 
four transmissible blastomeres were II-3, II-4, II-6 and II-8.
Figure 3. A β –thalassemia PND case from CVS which demonstrates sample authenticity dispute. It shows that 
the fetus (II-2) does not share some of his haplotypes from his father (lacking shared haplotype [with mutation] 
from his father if the red haplotype is from the mother). Discrepancy in other marks on different chromosomes 
(13, 18 and 21) showed this fetus is not the biological child of the father. “NL” means normal or wild type allele.
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Discussion
β-thal is the most common hematological disorder in the Middle Eastern countries31. National Program for the 
Prevention of Thalassemia has been in effect since 1997 in Iran5,6. Since then, many different types of mutation 
have been diagnosed32. However, there still exist cases with hematological parameters indicating β-thal but no 
mutation can be found despite using all available techniques like sequencing, gap PCR, MLPA and NGS33,34.
We showed that using STR markers can be very helpful in several ways for performing either PGDs35 or in 
special cases of PNDs where hematological indices indicate that the parents are carrier/s of β-thal36, even when no 
mutation can be found using techniques like whole gene sequencing or MLPA37. In addition, haplotype analysis 
can be helpful when there is a time constraint to find the mutation and even confirming direct mutation analysis 
findings38.
Although linkage analysis is very practical, it has some limitations such as some markers may not be inform-
ative in some families or no other number of the family is available for genotyping39,40. The performance of 
Figure 4. Paternity test result, (A) fetus DNA profile using GT-detector, (B) father’s DNA profile. These two 
have several unshared markers.
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homozygosity mapping is highly depending on markers heterozygosity. Another limitation is that it can’t be used 
if involvement of beta-globin gene is not 100% confirmed.
Regarding aborting affected fetuses, there is a religious decree and also a law allowing legal abortion in Iran. 
The law has been in effect since 2006 and religious decree since 19964. For PGDs we have the habit to ask the fam-
ily to undergo PND at 11–16 weeks’ gestation to avoid any misdiagnosis either at molecular stage or at embryo 
transfer. To date we have not had any misdiagnosis for beta-thalassemia and also if a family refuses to do PND, 
Figure 5. Schematic representation of a PGD result for beta-thalassemia and aneuploidy. As it is shown 
the assigned haplotypes are shown underneath each blastomere, parents and the affected child. The order of 
corresponding STR markers are shown on left. I-1 (father) is a carrier of IVSI-6 mutation and I-2 (mother) is 
carrier for IVSI-1. II-1 is the affected child of the family. II-2 is the female blastomere affected with β-thal, II-3 
is a male who carriers IVSI-1 mutation, II-4 is normal male, II-5 is affected male, II-6 is carrier male, II-7 is 
normal female but who is affected with monosomy 21, II-8 is a normal female, II-9 a is normal female but is 
affected with trisomy 21. The conclusion is that II-3, II-4, II-6 and II-8 are not affected and were reported to the 
































Size range 290–325 140–200 300–360 120–180 210–290 125–210 305–348 238–275 264–292 206–295 337–375 196–224 166–194 140–220 300–384
Matching 
Probability 0.109 0.067 0.171 0.15 0.15 0.081 0.13 0 0.069 0.083 0.068 0.108 0.16 0.068 0.094
Expressed as 
1 in… 9.2 14.9 5.9 6.7 6.7 12.3 11.5 6.6 14.5 12 15.1 9.1 6.1 14.8 10.6
PD* 0.857 0.924 0.868 0.866 0.761 0.908 0.921 0.771 0.925 0.917 0.881 0.854 0.865 0.932 0.906
PIC 0.74 0.78 0.64 0.69 0.75 0.75 0.77 0.76 0.82 0.9 0.77 0.75 0.62 0.89 0.91
PE** 0.215 0.413 0.528 0.599 0.407 0.543 0.523 0.551 0.648 0.463 0.421 0.217 0.525 0.825 0.928
Typical 
Paternity Index 1.06 1.61 2.09 2.5 1.59 2.17 2.54 1.45 2.88 1.8 1.72 1.05 2.05 5.83 14
No. of Alleles 8 9 6 6 5 11 12 5 8 15 9 8 6 11 14
Het obs 0.422 0.724 0.724 0.737 0.557 0.684 0.692 0.513 0.770 0.788 0.701 0.518 0.785 0.909 0.964
Het exp 0.744 0.787 0.733 0.726 0.590 0.764 0.782 0.575 0.821 0.901 0.68 0.615 0.734 0.932 0.917
P HWE P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.01 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
Table 1. Statistical findings of HBB STR markers. PD stands for power of discrimination, PE: power of 
exclusion, PIC: polymorphic information content, Het obs: observed heterozygosity, Het exp: expected 
heterozygosity, PHWE: significane of deviation from Hardy–Weinberg equilibrium.
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we do not force them. Regarding embryo transfer, in most PGD cases (except in few hemophilia A or B cases in 
which families have insisted in not transferring carrier female embryos) we suggest that both homozygous nor-
mal and heterozygote carriers’ embryos be transferred.
We showed that this newly released HapScreen kit can overcome these problems since different 
tetra-nucleotide repeat markers with a high rate of heterozygosity have been added into the kit to reduce the rate 
of stutter artifacts which is usually seen in dinucleotide repeat units41. In addition, to minimize the possibility of 
meiosis recombination, physical distances of newly selected markers to the gene have been chosen to be less than 
1Mbp. To further assess the suitability of the markers, allele frequency and heterozygosity of each STR marker 
were calculated in at least 100 unrelated individuals.
Using multiplex-PCR in linkage analysis, not only requires less time, reagents and labor work; it also decreases 
the sampling error rate. More importantly, it compensates the problem of insufficiency of blastomeric DNA used 
in PGD. Determining sample authenticity is an important issue in PND and PGD. There is a 50% similarity of 
haplotypes between the fetus and the mother; therefore, it is of great significance to confirm that the sample 
belongs to the fetus and it is not merely a result of maternal cell contamination. By adding nine markers from 
different chromosomes in addition to seven markers linked to the HBB gene, it seems very unlikely that two indi-
viduals would have the same haplotype.
Errors can arise in every stage of CVS or amniocentesis in twin pregnancies. Therefore, the kit has a tool to 
differentiate between fetuses in twin or multiple pregnancies or between samples which have under gone PND 
testing (i.e. parental, sibs and fetuses’), to reduce the rate of errors. By choosing multiple markers from different 
chromosomes (i.e. chromosomes 6, 21, 18, 13, X and Y), the chance of observing the same haplotype in differ-
ent individuals would be reduced. Therefore, this important feature would be very helpful to rule out maternal 
contamination, sampling errors, investigating sample authenticity and differentiation of fetal samples in multiple 
pregnancies. It can also confirm triploidy or uniparental disomy.
To achieve these goals, the manufacturer could have selected these markers from markers that are used in 
different human identification kits (e.g. GT-Detector human identification kit, GT), but they have preferred to 
choose them from chromosomes that are major cause of common aneuploidies42. In addition, to achieve the 
above mentioned goals, these markers allow early screening for common aneuploidies and sex determination in 
fetal samples and blastomeres cells.
We have been able to use HapScreen in several hundreds of our PND and PGD cases with no shortcomings 
and we think it adds credibility to every PND and PGD and also increases diagnostic accuracy and peace of mind 
in a discipline prone to misdiagnosis.
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and more 
information that support the findings of this study will be available on request from the corresponding.
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